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Abstract 
Protein nanoparticles such as virus-like particles (VLPs) can be obtained by 
recombinant protein production of viral capsid proteins and spontaneous self-
assembling in cell factories. Contrarily to infective viral particles, VLPs lack 
infective viral genome while retaining important viral properties like cellular 
tropism and intracellular delivery of internalized molecules. These properties 
make VLPs promising and fully biocompatible nano-vehicles for drug delivery.  
VLPs of human JC virus (hJCV) VP1 capsid protein produced in Escherichia coli 
elicit variable hemagglutination properties when incubated at different NaCl 
concentrations and pH conditions, being optimal at 200 mM NaCl and at pH rage 
between 5.8 and 7.5. In addition, the presence or absence of chaperone DnaK in 
E. coli cells influence the solubility of recombinant VP1 and the conformational 
quality of this protein in the VLPs. 
The hemagglutination ability of hJCV VP1 VLPs contained in E. coli cell extracts 
can be modulated by buffer composition in the hemagglutination assay. It has 
been also determined that the production of recombinant hJCV VP1 in E. coli is 
favored by the absence of chaperone DnaK as observed by Western Blot 
analysis in different E. coli genetic backgrounds, indicating a proteolysis targeting 
role for DnaK. However, solubility is highly compromised in a DnaK- E. coli strain 
suggesting an important role of this chaperone in reduction of protein 
aggregates. Finally, hemagglutination efficiency of recombinant VP1 is directly 
related to the presence of DnaK in the producing cells. 
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Introduction 
The Human JC polyomavirus (hJCV) belongs to the family Polyomaviridae and is 
widespread throughout the human population. It causes progressive multifocal 
leukoencephalopathy (PML) in immunocompromised individuals1,2 and it has 
been also associated to cancer.3 The capsid of the viruses of this family is 
composed of three structural proteins, VP1, VP2 and VP3. VP1 is the major 
capsid protein forming the outer shell of the virus shell through the spatial 
assembly of 72 VP1 pentamers. VP2 and VP3 are involved in the interaction 
between the core of the viral particle and the capsid and are essential in the virus 
life cycle.4-7 However, capsids formed exclusively of VP1 (hJCV VP1 virus-like 
particles-VLPs) can be obtained in heterologous expression systems including 
Escherichia coli, yeasts, mammalian cells and insect cell-baculovirus expression 
systems.8-14 An interesting feature of VLPs is their ability to self-assemble, which 
can be controlled experimentally allowing the internalization of dyes, nucleic 
acids, drugs or proteins in vitro.10,15-17 In addition, VLPs can be functionalized 
with cell ligands allowing the specific delivery of the cargo to target cells.18,19 
Interestingly, many VLPs have been proved to elicit sustained immune response 
in vaccination regimes.20 However, the administration of hJCV VP1 VLPs without 
adjuvant is not able to stimulate any immune response,9 making this type of 
VLPs suitable as nanovehicles for biotechnological and nanomedical 
applications. 
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Expression of viral proteins of eukaryotic hosts in prokaryotic expression systems 
copes with several difficulties. On the one hand, the prokaryotic expression 
system lacks many of the eukaryotic posttranslational modifications such as 
glycosylation or the formation of disulfide bonds in the oxidizing cytosol. In 
addition, the finely tuned chaperone-protease pathways of the protein quality 
control system are believed to be limiting in expressing cells. In that sense, it has 
been demonstrated that overexpression or depletion of chaperones has a 
significant effect over recombinant protein yield and conformational quality, being 
these parameters not necessarily coincident. Assembly of polyomavirus VLPs 
both in vivo and in vitro seems to be favored by Hsp70 family chaperones in both 
eukaryotic and prokaryotic systems and is inhibited by the presence of Hsp60 
family chaperones.21,22 In this work, we have studied the effect of the bacterial 
DnaK chaperone on the production, solubility and hemagglutination activity of 
hJCV VP1 VLPs, and the influence of this chaperone on the supramolecular 
organization of polyomavirus VLPs in vivo. DnaK is a folding chaperone that 
promotes the correct protein folding in cooperation with its co-chaperone DnaJ, 
and assisted by the nucleotide exchange factor GrpE.23,24 The results obtained 
show that, in the presence of DnaK, the total amount of recombinant hJCV VP1 
recombinant protein is negatively affected although the solubility and biological 
activity is significantly improved. Then, the increase in solubility is translated into 
an enhanced conformational quality as the protein obtained in DnaK- genetic 
background shows higher titer in hemagglutination assays.  
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Material and methods 
hJCV VP1 gene cloning and E. coli strains 
The human JCV VP1 gene (Jvgp4, NC_001699.1) was codon optimized for E. 
coli expression and provided by Geneart (Regensburg, Germany). The artificial 
gene (KF488587) was cloned into pTrc99A expression vector (Amersham 
Pharmacia Biotech, catalog no. 275007-01) by using NcoI-BamHI (Roche) 
restriction sites and transformed in E. coli DH5α strain (Invitrogen). Expression of 
JCV VP1 gene was under transcriptional control of the Isopropyl-beta-D-
thiogalactopyranoside (IPTG) inducible promoter Ptrc.  
Plasmid pTrc99a-VP1 was transformed by heat shock pulse into three different 
E. coli expression strains: the pseudo wild type MC4100 [F− araD139 ∆(argF-lac) 
U169 rspL150 relA1 flbB5301 deoC1 ptsF25 rbsR, StrepR],25 its DnaK- derivative 
JGT20 [MC4100 dnaK thr::tn10, StepR, TcR, CGSC#: 6152]25 and MC4100 
bearing pBB53526 that harbours IPTG-inducible, PA1/lac-O1-controlled DnaK-J 
chaperone genes. 
 
hJCV VP1 production and purification 
The transformed E. coli cells were cultured overnight in LB medium at 37ºC. The 
starter culture was then diluted at 1/20 with LB to a final volume of 500 ml and 
the mixture cultured again at 37ºC until the optical density at 550 nm reached 
0.5. The gene expression was induced by the addition of IPTG to final 
concentration of 0.5 mM. Cells were incubated at 30ºC for 4 hours, and 65 ml of 
the culture were then separated and cells harvested (15,000g for 15 min at 4ºC), 
washed with phosphate buffered saline (PBS) and harvested again. Pellets were 
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suspended in 6.5 ml of PBS with EDTA-free protease inhibitor cocktail Complete 
(Roche, catalog no. 11873580001). Cells were disrupted by two 10 min-
sonication cycles at 40 %-50 % amplitude with a Labsonic U sonicator, 8-mm 
probe (B. Braun Biotech International, Melsungen, Germany). Soluble and 
insoluble fractions were separated by centrifugation. 
Protein detection was performed by Western blotting in protein samples resolved 
in 10 % SDS-PAGE transferred onto a nitrocellulose membrane. After blocking 
with 5 % milk O/N, the nitrocellulose membrane was incubated with mouse 
monoclonal to Human Polyomavirus JCV capsid protein VP1 primary antibody 
(Abcam, catalog no. ab34756) at a dilution of 1:1,500 in PBS. For detection, a 
1:2000 diluted goat anti-mouse IgG (H+L)-HRP conjugate antibody (Bio-Rad) 
was used. Recombinant hJCV Polyomavirus Major Capsid VP1 Protein (Abcam, 
catalog no. ab74569) was used as protein standard in protein quantification 
experiments; for that, protein samples were loaded containing increasing 
amounts of recombinant protein: 15 ng, 30 ng, 60 ng, 90 ng, 120 ng and 240 ng. 
The protein amount (µg ml-1 culture was normalized according to optical density 
at 550 nm). 
 
Hemagglutination assays.  
Detection of red blood cell (RBC) hemagglutination was performed by mixing 0.1 
µg of hJCV VP1 (obtained from E. coli lysates and adjusted to a final volume of 
50 µl with PBS) with 50 µl of 0.5% chicken RBCs, kindly provided by Gerard 
Eduard Martin Valls from CReSA (Universitat Autònoma de Barcelona), in a 
serial two fold dilution in 96 well plates. Samples were incubated for 
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approximately 48 h at 4ºC and then observed. Different buffers were used in 
hemagglutination assays: Tris 20 mM, 0/40/110/150 mM NaCl, 1 mM MgCl2, 1 
mM CaCl2, pH7.5 and also Tris 20 mM, 200 mM NaCl, 1 mM MgCl2, 1 mM 
CaCl2, pH 5.8/7.5/9. The hemagglutination titer for each sample has been 
calculated as the median value from three different plates taking into account that 
50 µl (containing 0.1 µg of protein) is the initial volume. Briefly, the individual titer 
for each point in the data set corresponds to the highest dilution factor that 
produced a positive reading. This value is then corrected to ml by a factor of 20 
giving HA Units/ml. 
 
Transmission electron microscopy (TEM) 
E. coli MC4100/pBB535 soluble cell fraction was loaded on 40 % sucrose 
cushion and centrifuged at 100,000 g at 4°C for 4h (Beckman SW27 swinging 
bucket rotor). Resulting pellet was dissolved in Tris 20 mM, 150 mM NaCl, 1 mM 
MgCl2, 1 mM CaCl2, pH7.5 buffer. Sample was applied on carbon coated grids 
and negatively stained with uranyl acetate 2 % [w/v] aqueous solution.  
Photographs were taken with JEM-1400 transmission electron microscope at 
250000 X nominal magnification. 
 
Statistical analysis.  
Significance of differences between means of recombinant protein production in 
the insoluble, soluble and total cell fractions were evaluated by a Student’s t-test. 
Each experiment was performed in triplicate in intra and inter experiments. 
Briefly, each data point presented in the graphs corresponds to the results 
Page 8 of 21
John Wiley & Sons
Biotechnology Progress
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9
obtained in three independent experiments and each experiment was performed 
in triplicate. Therefore, nine different measures have been analized for each data 
point. 
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Results and discussion 
In vitro stabilization of VP1 VLPs produced in wild type E. coli  
Production of recombinant human JCV VP1 has been described in several 
expression systems including E. coli, yeast, insect cells-baculovirus and 
mammalian cells. In all cases, the presence of the VLPs has been demonstrated 
by using the hemagglutination assay or by transmission electron 
microscopy.8,9,12,14 In this study we wanted to determine the effect of the 
incubation buffer on the efficiency of VP1 VLPs assembly in cell extracts. For that 
reason, chicken red blood cells were incubated with VP1 VLP containing 
samples produced in an E. coli wild type genetic background under different 
buffer conditions (Fig. 1a). It has b en described the importance of the presence 
of Ca2+ and oxidizing conditions in the stability of the SV40 and hJCV VLPs. In 
fact, the formation of the VLPs depends on the interaction of Ca2+ within the GH 
loop and probably on the presence of disulfide bonds between CD loops of 
neighboring capsomeres.8 Therefore, a buffer containing Ca2+ and Mg2+ was 
selected and different monovalent ion concentration and pH conditions were 
tested regarding the stability of hJCV VP1 VLPs. The results show that the 
presence of NaCl is a favoring factor, being optimal at 200 mM. At higher 
concentrations (1 M), a clear interference with the hemagglutination assay was 
detected (Fig. 1b). The dependence in monovalent ions on the assembly of VP1 
VLPs has been also demonstrated for SV40 VP1 in insect cell nuclear extracts 
and it seems to be related to the presence of cellular factors.27 The influence of 
pH was also tested showing better hemagglutination performance at pH ranging 
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from 5.8 to 7.5 in the 200 mM NaCl containing buffer (Fig. 1c). VP1 VLPs stability 
was compromised at higher pH values in the same buffer. Consequently, the 
hemagglutination buffer used in subsequent experiments contained 200 mM 
NaCl and it was adjusted to pH=7.5. 
 
hJCV VP1 expression in diverse E. coli DnaK genetic 
backgrounds 
The production of recombinant proteins in heterologous expression systems 
provokes a stress situation in the cell factory leading, in most cases, to the 
accumulation of the protein of interest in insoluble structures known as inclusion 
bodies (IBs). The formation of IBs in expression experiments is enhanced by the 
limitation of the chaperone/protease system and therefore, the increase in the 
amount of chaperones has been used as a strategy to overcome this limitation 
with the final aim to increase the amount of recombinant protein in the cellular 
soluble fraction.28,29 In summary, the results obtained so far by using several 
chaperone cocktails suggest that, overall; solubility takes priority over 
conformational quality. Consequently, the more recombinant protein is present in 
the soluble fraction the less biological activity is retained.30-32 However, most of 
the studies performed so far are related to proteins that are not able to form 
protein complexes and only few of them describe the influence of chaperones in 
the production of protein complexes as VLPs.21 Therefore, in order to gather 
information related to the influence of chaperones on the production of protein 
complexes, we have studied the effect of the presence of DnaK, a bacterial 
chaperone of the Hsp70 family on the production of JCV VP1. We transformed 
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wild type E. coli MC4100, E coli MC4100 DnaK- (JGT20) and E. coli 
MC4100/pBB535 with an expressing vector coding the VP1 hJCV gene and 
induced its expression under standard conditions. The total amount of 
recombinant protein was significantly higher in Dnak- E. coli strain, and the 
presence of DnaK in MC4100 had a profound negative effect on protein yield 
(Fig. 2a). In addition, the fourfold increase in DnaK concentration in 
MC4100/pBB535 E. coli strain33 did not promote further reduction in protein 
production. This result might indicate a limited access of overexpressed DnaK to 
available DnaJ and GrpE cellular levels. However, when soluble and insoluble 
cellular fractions were individually analyzed, wild type MC4100 and DnaK 
overexpressing MC4100/pBB535 E. coli cells presented higher soluble/insoluble 
protein ratio and contained significantly more soluble protein than E coli MC4100 
DnaK- (JGT20) (Fig. 2b). Under the tested experimental conditions, expression of 
the chaperone DnaK enhances the solubility of VP1 hJCV in the cell although it 
also induces a reduction in protein yield. 
 
Hemagglutination assays of recombinant hJCV VP1 VLPs 
produced in E. coli. 
 
The effect in biological activity of hJCV VP1 VLPs produced in the presence of 
different amounts of DnaK was determined by analyzing their ability to 
hemagglutinate red blood cells (Fig. 3a). In those experiments, the same amount 
of recombinant hJCV VP1 was used and VP1 concentration in cell extracts was 
calculated by Western blot using standard VP1. The used incubation buffer was 
Page 12 of 21
John Wiley & Sons
Biotechnology Progress
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 13
the optimized reaction buffer selected in the stabilization experiments described 
above. In those experiments, an E. coli cell extract lacking VP1 has been used 
as negative control. The hemagglutination assay showed that in all three E. coli 
genetic backgrounds, VP1 forms VLPs that can hemagglutinate RBC. In addition, 
the presence of 42-45 nm particles obtained after ultracentrifugaction of E. coli 
MC4100/pBB535 cell extracts confirmed the formation of VLPs under 
experimental conditions (Fig. 3b). However, the presence of DnaK has a positive 
effect on the ability of VP1 VLPs to hemagglutinate RBC indicating a direct effect 
of DnaK on the correct assembly of these protein supramolecular assemblies. In 
addition, it can be seen that when comparing hemagglutination activity on DnaK 
containing lysates the overexpression of DnaK had no effect (Fig. 3c). 
 
Conclusions 
Stability of VLPs depends on several factors as oxidative environment and 
divalent ion concentration among others. It has been demonstrated that pH and 
monovalent cations are also relevant for the correct assembly of hJCV VP1 as 
they might collaborate in van der Waals interactions.34 
Cellular protein quality control is accomplished by the coordinated action of 
chaperones and proteases acting on nascent polypeptides for protein folding and 
holding, sending folding reluctant intermediates to the proteolysis pathway or 
accumulating them in dynamic protein based structures (IBs) for further 
processing through either folding or proteolysis. The general outcome of this 
process is improvement on protein solubility, defined as the portion of protein 
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present in the soluble fraction of the cell. In this work, it has been demonstrated 
the positive effect on solubility observed in the presence of DnaK chaperone in 
recombinant hJCV VP1 production. In addition, saturation in solubility seems to 
be reached at DnaK concentration obtained in wild type E. coli genetic 
background since fourfold higher concentration of DnaK in MC4100/pBB535 is 
not translated in an increase VP1 solubility (Fig. 3b). In addition, the presence of 
DnaK seems to target hJCV VP1 to proteolysis pathway since production of VP1 
is dramatically reduced in MC4100 and MC4100/pBB535 E. coli strains. 
Production of VP1 of related polyomavirus simian virus 40 (SV40) in E. coli is 
also dependent on the presence of chaperones although in this case, the 
presence of DnaK produces an increase in the yield of SV40 VP1.21 In this study, 
the different induction conditions used might account for the dissimilar results (2 
h at 30ºC instead of 4 h at 30ºC). On the other hand, in eukaryotic expression 
systems, heat shock cognate protein 70 (hsc70), one of the Hsp70 family 
member, is involved in the in vivo assembly of polyomavirus VP1 VLPs in the 
nuclei while in prokaryotes DnaK, one of the Hsp70 family prokaryotic 
counterparts, recognizes the C-terminus of VP1 and enhances VP1 
assembly.17,21 Therefore, the positive effect on hemagglutination efficiency in 
DnaK producing E. coli strains is in accordance with direct interaction of DnaK 
with recombinant hJCV VP1. This result contrasts with the production of 
recombinant proteins that do not form supramolecular structures. In this scenario, 
it has been demonstrated that biological activity is not necessarily favored when 
gaining solubility. In fact, a wide spectrum of soluble species can be found in the 
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soluble fraction of induced cells.21,35 This study reveals the positive impact of 
DnaK on solubility and conformational competence of multiprotein complexes 
formed by hJCV VP1 which give priority to protein yield that is negatively affected 
in a DnaK-positive genetic background. 
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Figure 1. Hemagglutination assays of 0.1 µg of hJCV VP1 VLPs obtained in E. coli soluble cell 
fraction under different NaCl concentrations (A). Hemagglutination assays of hJCV VP1 VLPs 
obtained in the E. coli soluble cell fraction under different pH conditions in 200 mM NaCl in Tris 
buffer (B). Control wells show the hemagglutination activity of a negative E. coli cell extract under 
different buffering conditions. Effect of NaCl concentration on red blood cell precipitation in the 
absence of E. coli cell extract (C). 
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Figure 2. Protein quantification by Western blot of JCV VP1 VLPs in total, soluble and insoluble 
cell fractions using commercial VP1 as standard (A). Relative JCV VP1 VLPs presence in soluble 
cell fractions (B). Asterisks indicate significant differences when comparing with any other data 
group (*p<0.05; **p<0.01 and ***p<0.001). The amount of protein was normalized according to 
OD550nm. 
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Figure 3. Hemagglutination assay of JCV VP1 containing E. coli lysates (A). Negative control 
wells (C-) correspond to MC4100 E. coli strain lysates lacking JCV VP1. Quantification of HA 
activity of 0.1 µg of hJCV VP1 VLPs obtained in different E. coli genetic backgrounds (B). Purified 
JCV VP1 obtained from E. coli MC4100/pBB535 induced cell lysates (C). 
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